2025.2.10
First patient was enrolled in a Phase 3 clinical trial for pancreatic cancer in Japan.
2024.8.26
We submitted a Phase 3 clinical trial notification for pancreatic cancer in Japan to the Pharmaceuticals and Medical Devices Agency (PMDA).
2024.7.18
Results from preclinical study will be presented by Dr. Juanjuan Ye at the 83rd Annual Meeting of the Japanese Cancer Association (Fukuoka, September 19-21, 2024).
Title：Pancreatic tumor suppression by anti-PD-1 antibody and stroma modifying RNA oligonucleotide STNM01 in mice
Presentation No.：E14-4
Presentation Type：English Oral Session
Date and Time：Sep. 20 (Fri.) 13:00-14:15
The 83rd Annual Meeting of the Japanese Cancer Association
https://site.convention.co.jp/jca2024/en/
2024.6.20
Results from preclinical study were published by Dr. Juanjuan Ye in Molecular Therapy Oncology.
Title: Intra-tumoral administration of CHST15 siRNA remodels tumor microenvironment and augments tumor-infiltrating T cells in pancreatic cancer.
2024.5.31
Results from preclinical study were presented by Dr. Juanjuan Ye at American Society of Clinical Oncology (ASCO) annual meeting 2024.
Title: Robust pancreatic tumor suppression by a novel combination treatment with anti-PD-1 immune checkpoint antibody and stroma modifying RNA oligonucleotide STNM01 in mice.
https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.e14630
2024.5.21
Results from preclinical study were presented by Dr. Juanjuan Ye at the Digestive Disease Week (DDW) annual meeting 2024.
Title：LOCOREGIONAL INJECTION OF RNA OLIGONUCLEOTIDE TARGETING CARBOHYDRATE SULFOTRANSFERASE 15 DIMINISHES BOTH TUMORAL AND LYMPH NODE MDSCS AND ACCELERATES T CELL INFILTRATION IN PANCREATIC TUMOR IN MICE
Presentation Type：Poster Session
Date and Time：May 21, 2024 from 12:30 PM to 1:30 PM EDT (UTC –4)
2023.7.12
Results from preclinical study will be presented by Dr. Juanjuan Ye at the 82nd Annual Meeting of the Japanese Cancer Association (Yokohama, September 21-23, 2023).
Title：Targeting carbohydrate sulfotransferase 15 diminishes both tumoral and lymph node MDSCs in pancreatic tumor in mice
Presentation No.：E-3051
Presentation Type：English Oral Sessions
Date and Time：Sep. 23 (Sat.) 13:30-14:45
The 82nd Annual Meeting of the Japanese Cancer Association
2023.7.3
Results from preclinical study were presented by Dr. Juanjuan Ye at the 2nd JCA-AACR* Precision Cancer Medicine International Conference (Kyoto, June 28-30, 2023).
*JCA-AACR : Japanese Cancer Association (JCA)/American Association for Cancer Research (AACR)
Title: Silencing of Tumoral Carbohydrate Sulfotransferase 15 Reactivates Lymph Node T cells in Pancreatic Cancer in Mice
Presentation Type: Poster
2023.6.2
Results from preclinical study were presented by Dr. Juanjuan Ye at American Society of Clinical Oncology (ASCO) annual meeting 2023.
Title: Effect of locoregional injection of RNA oligonucleotide targeting carbohydrate sulfotransferase 15 on both tumoral and lymph node MDSCs and T cell infiltration in pancreatic tumor in mice.
https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.e16310?af=R
2023.5.30
Results from preclinical study were published by Dr. Juanjuan Ye in European Journal of Immunology.
Title: Silencing of tumoral carbohydrate sulfotransferase 15 reactivates lymph node pancreatic cancer T cells in mice.
https://onlinelibrary.wiley.com/journal/15214141
https://pubmed.ncbi.nlm.nih.gov/37248998/
2022.11.18
The results from Phase 1/2a clinical study of STNM01 as a second-line therapy for unresectable pancreatic cancer were published in the LANCET eClinicalMedicine.
Fujisawa T et al. STNM01, the RNA oligonucleotide targeting carbohydrate sulfotransferase 15, as second-line therapy for chemotherapy-refractory patients with unresectable pancreatic cancer: An open label, phase I/IIa trial. The LANCET eClinicalMedicine 2023;55: 101731
https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(22)00461-8/fulltext
2022.6.2
Final results from Phase 1/2a clinical study of STNM01 as a second-line therapy for unresectable pancreatic cancer were presented by Dr. Tsuchiya at American Society of Clinical Oncology (ASCO) annual meeting 2022.
https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.4144
2022.6.2
Results from preclinical study were presented by Dr. Ye at American Society of Clinical Oncology (ASCO) annual meeting 2022.
Title: Effect of silencing tumoral carbohydrate sulfotransferase 15 on T cells in a murine model of pancreatic cancer.
https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.e16241
2022.5.22
Results from preclinical study were presented by Dr. Ye at Digestive Disease Week (DDW) annual meeting 2022.
Title: Silencing of tumoral carbohydrate sulfotransferase 15 augments tumor-infiltrating T cells with boosted lymph node T cell priming in a murine model of pancreatic cancer
2022.5.21
Final results from Phase 1/2a clinical study of STNM01 as a second-line therapy for unresectable pancreatic cancer were presented by Dr. Tanisaka at Digestive Disease Week (DDW) annual meeting 2022.
Title: Locoregional injection of the RNA oligonucleotide targeting carbohydrate sulfotransferase 15 is able to accelerate tumor-infiltrating T cells in patients with unresectable pancreatic cancer, refractory to first-line chemotherapy
2021.6.4
Top-line results from Phase 1/2a clinical study of STNM01 as a second-line therapy for unresectable pancreatic cancer were presented by Dr. Tsuchiya at American Society of Clinical Oncology (ASCO) annual meeting 2021.
Title: A phase I/IIa trial of the RNA oligonucleotide STNM01 by EUS-FNI to investigate the safety and efficacy in patients with first-line refractory, unresectable pancreatic cancer.
https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.15_suppl.4120
2018.4.26
Results of IIT for unresectable pancreatic cancer was published in GIE.
Nishimura M, et al. Effects of EUS-guided intratumoral injection of oligonucleotide STNM01 on tumor growth, histology, and overall survival in patients with unresectable pancreatic cancer. Gastrointest Endosc. 87:1126-1131, 2018.
2018.3.22
Phase 1/2a IIT program for unresectable pancreatic cancer was adopted by AMED innovative research program.